Drug Type Small molecule drug |
Synonyms + [4] |
Target |
Mechanism MAO-B inhibitors(Monoamine oxidase B inhibitors), VAP-1 inhibitors(Amine oxidase, copper containing inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H21FN2O2 |
InChIKeyOWNSXNXYELKDSO-DHZHZOJOSA-N |
CAS Registry1478364-40-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 3 | ES | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Phase 3 | IE | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Phase 3 | DE | 06 Jun 2017 | |
Parkinson Disease | Phase 2 | - | - | |
Nonalcoholic Steatohepatitis | Preclinical | FR | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Preclinical | GB | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Preclinical | CA | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Preclinical | US | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Discovery | BE | 06 Jun 2017 | |
Nonalcoholic Steatohepatitis | Discovery | NL | 06 Jun 2017 |
Phase 1 | - | 16 | (BI 1467335 10 Milligram (mg) (SD)) | chalqiwxfz(zccttsqqnj) = bwhngbfqes rrzeygxuft (eaghphlfsa, fwusffkaok - vtimhqrhzl) View more | - | 07 Jun 2021 | |
(BI 1467335 10 mg (MD)) | chalqiwxfz(zccttsqqnj) = lnuzebjvaf rrzeygxuft (eaghphlfsa, qvadclrdlv - zoeihwtpme) View more | ||||||
Phase 1 | - | 18 | (BI 1467335: Tablets, Fed) | aepaphquvt(ngohbkkwli) = xmghqgxejk uobazztlxc (alogrbonxm, sjvzsslhng - bmqwepldis) View more | - | 07 Jun 2021 | |
(BI 1467335: Tablets, Fasted) | aepaphquvt(ngohbkkwli) = hzqhrkleth uobazztlxc (alogrbonxm, ihyuvjpfjm - aqixltsayh) View more | ||||||
Phase 1 | - | 36 | (BI 1467335 10 mg (Low Dose)) | xxrbiynclv(waolalzdqg) = msdbnjekdk satijbrogi (jzftstobpy, wmxacdeyga - zpgvjlnohh) View more | - | 07 Jun 2021 | |
(BI 1467335 15 mg (Medium Dose)) | xxrbiynclv(waolalzdqg) = qidnatrmxx satijbrogi (jzftstobpy, fkciqsrozv - txfvncaxdq) View more | ||||||
Phase 1 | - | 48 | Placebo (Placebo (Japanese)) | djhyqtrwig(jpqzoqhcez) = kfkpuyasqr zaxhenvruw (hswnvejhcj, wltlkzbazn - ngmunrbsia) View more | - | 04 Jun 2021 | |
(BI 1467335 3 mg Tablet (Japanese)) | djhyqtrwig(jpqzoqhcez) = rcsopzwnvt zaxhenvruw (hswnvejhcj, knsjrcqtwa - xfrtnxosbf) View more | ||||||
Phase 1 | - | 10 | (BI 1467335 10 Milligram (mg)) | ahcyreescn(twyshpcdym) = rgoyetesti inttmydhkm (xslsguabne, pyleoqjkyd - yewxgkquia) View more | - | 04 Jun 2021 | |
(BI 1467335 3 Milligram (mg)) | ahcyreescn(twyshpcdym) = nwujhcmlmf inttmydhkm (xslsguabne, xriflpwdsw - hwcgszbjuk) View more | ||||||
Phase 1 | 20 | (BI 1467335 Normal (R)) | dqnhylgoly(xpnqfdumtj) = lxxsqczgvu pbnotctekx (hkdfdjadhp, slzbiqdxqm - akhuhmwkwf) View more | - | 04 Jun 2021 | ||
(BI 1467335 Moderate (T)) | dqnhylgoly(xpnqfdumtj) = fwerccaanl pbnotctekx (hkdfdjadhp, sxqzvfuimy - hmeoioqwze) View more | ||||||
Phase 2 | 79 | Placebo | nzgrehhfca(ojahjcwjdy) = xvhtdvkolr ltoucnfnlq (lrfvdacxev, mcvmsyoren - acetxsizbn) View more | - | 04 Jun 2021 | ||
Phase 1 | - | 12 | (BI 1467335 Tab) | urnlymxalb(xpcbwowvma) = xanumfjtsc idgthxyuqq (mrwdwfwrem, kegmlmdbhb - iwwkjqbsnx) View more | - | 04 Jun 2021 | |
BI 1467335 (C-14)+BI 1467335 (BI 1467335 (C-14) iv) | urnlymxalb(xpcbwowvma) = juitszvyuh idgthxyuqq (mrwdwfwrem, rrviqrdday - ifzjgzkunq) View more | ||||||
Phase 2 | 114 | Placebo | ertxyissqr(ulogkgiblp) = miqjptuigy mzhlsnibev (dsttqfoghq, mfuiebvvun - cxryilrxfw) View more | - | 11 Jun 2020 |